Convergence of plasmid-driven virulence and antibiotic resistance in Escherichia coli.
Lian. Zheng Jie ZJ; Nhu. Nguyen Thi Khanh NTK; Ravi. Chitra C; Chang. Chyden C; Martinez-Roman. Irene I; Phan. Minh-Duy MD; Schembri. Mark A MA
Key Findings
- ColV-like plasmids split into four groups with different mixes of virulence and antibiotic‑resistance genes
- Some groups carry high‑level resistance, even to last‑resort drugs like colistin
- A plasmid‑encoded outer‑membrane protease (OmpTp) works with the bacterial chromosome to protect E. coli from the human peptide LL‑37
Practical Outcomes
- For the DIY health community, this study mainly raises awareness that certain bacterial strains can become tougher against both antibiotics and the body’s own defenses, but it doesn’t offer new protocols or direct actions for personal health optimization.
Summary
Scientists found that certain E. coli bacteria carry plasmids (small DNA circles) that not only make them resistant to many antibiotics but also help them dodge the body’s natural antimicrobial peptide LL‑37, which is part of the immune defense in the urinary tract.
Abstract
Plasmids are major vehicles for the spread of antibiotic resistance genes. Some plasmids additionally carry virulence genes that enhance host pathogenicity. The convergence of resistance and virulence genes on the same plasmid poses significant risk, providing a mechanism to create pathogens that cause severe disease with limited treatment options. Colicin V (ColV)-like plasmids (ColVLPs) are virulence plasmids frequently carried by extra-intestinal pathogenic E. coli (ExPEC) that cause human and avian infection. Here, by generating and analysing a ColVLP database, we demonstrate that ColVLPs form four distinct sub-groups, characterised by genes encoding for Colicins V and M, with differing virulence and antimicrobial resistance gene carriage. Three of these sub-groups possess moderate-high resistance towards multiple antibiotic classes. We further describe ColVLP co-integrates that have acquired extensive resistance profiles, including against last line colistin, through recombination with co-resident plasmids. Using pMS7163A, a ColVLP from a virulent ExPEC strain, we also demonstrate that the ColVLP-encoded outer membrane protease virulence factor OmpTp works co-operatively with its chromosomal homolog to enhance ExPEC resistance against human cathelicidin (LL-37), an antimicrobial peptide expressed in the urinary tract. Together, our work characterises ColVLPs as high-risk mobile genetic elements that amplify the convergence of resistance and virulence in ExPEC.
Study Information
pubmed
2025
2025-12-10T00:00:00.000Z
10.1038/s41467-025-67202-9